Search

Cancer is one of the leading causes of death worldwide. The success rate of conventional anticancer therapeutic approaches such as chemotherapy is limited by the non-specific toxicity and low specificity towards specific tumors, which are highly dependent on the mutational burden present on each patient. Similarly, targeted therapies have proven to induce resistance in numerous malignancies. Therefore, immunotherapy has emerged as a better approach to discriminate between "the own" and "the non-own", which occurs through two types of mechanisms, innate and acquired immunity. Acquired immunity is one of the targets for new immunotherapeutic treatments, unleashing the power of antigen-specific T cells as a potential therapeutic weapon for cancer treatment. Thus, immunotherapy modifies the own immune system to increase the recognition and elimination of cancer cells by identifying these cancer antigens. One of the advantages of immunotherapy, when compared to conventional anticancer approaches, is the generation of long-term immunity (immunological memory). Currently, there are different potential types of immunotherapy in cancer to promote the modulation of the immune response. Among them, the use of cytokines, vaccines, viruses, monoclonal antibodies, and the generation of adaptive immune response cells have achieved successful results in some types of cancer.

Pancreatic cancer is a malignancy of great impact in developed countries and is having an increasing impact in Latin America. Incidence and mortality rates are similar for this cancer. This is an important reason to offer to the patients the best treatments available. During the Latin American Symposium of Gastroenterology Oncology (SLAGO) held in Viña del Mar, Chile, in April 2015, a multidisciplinary group of specialists in the field met to discuss about this disease. The main conclusions of this meeting, where practitioners from most of Latin American countries participated, are listed in this consensus that seek to serve as a guide for better decision making for patients with pancreatic cancer in Latin America.

Pancreatic cancer is a malignancy of great impact in developed countries and is having an increasing impact in Latin America. Incidence and mortality rates are similar for this cancer. This is an important reason to offer to the patients the best treatments available. During the Latin American Symposium of Gastroenterology Oncology (SLAGO) held in Vina del Mar, Chile, in April 2015, a multidisciplinary group of specialists in the field met to discuss about this disease. The main conclusions of this meeting, where practitioners from most of Latin American countries participated, are listed in this consensus that seek to serve as a guide for better decision making for patients with pancreatic cancer in Latin America.

A 45 years old male in whom a Hodgkin disease, nodular sclerosis variety, IIIBS, with splenectomy was diagnosed at the age of 27 years of age, is reported. He was treated initially with chemotherapy C-MOPP and radiotherapy, obtaining a complete remission of the disease two years later. In December 2000, after 17 years of remission, the disease relapsed with generalized lymph node enlargement and lung involvement. He was treated with ABVD chemotherapy, but died after 5 cycles due to a febrile neutropenia, bronchopneumonia and respiratory distress.

A 45 years old male in whom a Hodgkin disease, nodular sclerosis variety, IIIBS, with splenectomy was diagnosed at the age of 27 years of age, is reported. He was treated initially with chemotherapy C-MOPP and radiotherapy, obtaining a complete remission of the disease two years later. In December 2000, after 17 years of remission, the disease relapsed with generalized lymph node enlargement and lung involvement. He was treated with ABVD chemotherapy, but died after 5 cycles due to a febrile neutropenia, bronchopneumonia and respiratory distress (Rev Med Chile 2003; 131: 197-9)